| Bioactivity | S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC50 of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC50 of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis[1][2]. |
| CAS | 1538574-95-6 |
| Formula | C26H23ClN6 |
| Molar Mass | 454.95 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Weiler S, et al. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J Med Chem. 2014;57(12):5074-5084. [2]. Harris CM, et al. Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats. J Pharmacol Exp Ther. 2016;359(1):151-158. |
S1PL-IN-1
CAS: 1538574-95-6 F: C26H23ClN6 W: 454.95
S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC50 of 210 nM. S1PL-IN-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.